BRIEF-Gilead receives approval in Canada for expanded indication of epclusa
September 21, 2017 at 06:51 AM EDT
* Gilead receives approval in Canada for expanded indication of epclusa® (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV
